Verona Pharma
VRNA
VRNA was delisted on the 6th of October, 2025.
292 hedge funds and large institutions have $7.18B invested in Verona Pharma in 2025 Q2 according to their latest regulatory filings, with 70 funds opening new positions, 81 increasing their positions, 109 reducing their positions, and 32 closing their positions.
119% more first-time investments, than exits
New positions opened: 70 | Existing positions closed: 32
77.82% more ownership
Funds ownership: 11.41% → 89.23% (+78%)
57% more capital invested
Capital invested by funds: $4.58B → $7.18B (+$2.6B)
13% more funds holding
Funds holding: 258 → 292 (+34)
4% more funds holding in top 10
Funds holding in top 10: 28 → 29 (+1)
26% less repeat investments, than reductions
Existing positions increased: 81 | Existing positions reduced: 109
69% less call options, than puts
Call options by funds: $102M | Put options by funds: $328M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$117M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$78M |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$68.4M |
| 4 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$64.8M |
| 5 |
D.E. Shaw & Co
New York
|
+$59.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$107M |
| 2 |
MC
Maverick Capital
Dallas,
Texas
|
-$93.4M |
| 3 |
PA
Perceptive Advisors
New York
|
-$78.2M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$60.3M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$37.1M |
VRNA Hedge Fund Activity: Q2 2025 in Review
292 of the 3,746 institutional investors tracked by Wall St. Rank reported a position in Verona Pharma (VRNA) for Q2 2025, worth a combined $7.18B — up 57% from $4.58B a quarter earlier.
Buyers outnumbered sellers: 70 funds opened new VRNA positions and 32 closed out — a net gain of 38 holders — while 81 added to existing stakes and 109 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $117M. The largest seller was Morgan Stanley, cutting an estimated $107M.
- 292 institutional investors held Verona Pharma (VRNA) as of Q2 2025, up from 258 in Q1 2025.
- Funds reported $7.18B of Verona Pharma stock for Q2 2025, up 57% quarter-over-quarter.
- 70 funds opened new Verona Pharma positions in Q2 2025 and 32 closed out, a net change of +38 holders.
- The largest Verona Pharma buyer in Q2 2025 was Goldman Sachs, an estimated $117M added.
- The largest Verona Pharma seller in Q2 2025 was Morgan Stanley, an estimated $107M sold.
Based on aggregated 13F filings for Q2 2025.